Glutamic Acid Decarboxylase Antibody, CSF
Use
This test aids in the diagnosis of stiff-person syndrome, limbic encephalitis, and other autoimmune neurologic disorders. It may also be utilized for monitoring treatment response in individuals who are antibody positive. The presence of the antibody in cerebrospinal fluid (CSF) indicates an autoimmune etiology in neurological conditions. The assay is intended for the semi-quantitative determination of glutamic acid decarboxylase antibody in human CSF, providing essential information to clinicians in their diagnosis and management decisions.
Special Instructions
Not provided.
Limitations
This assay is developed and its performance characteristics determined by ARUP Laboratories, and it has not been cleared or approved by the US Food and Drug Administration. Results should be interpreted within the context of clinical symptoms. While the test provides valuable information, any value greater than 5.0 IU/mL is considered positive for the antibody; however, results must be correlated with clinical presentation and additional diagnostic tests as necessary.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Glutamic Acid Decarboxylase
Protein
LOINC Codes
- 42501-7 - GAD65 Ab CSF-aCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Transfer 1 mL CSF to an ARUP Standard Transport Tube.
Storage Instructions
Store and transport specimen frozen.
Causes for Rejection
Specimens other than CSF or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 1 week |
| Frozen | 3 months |
Other tests from different labs that may be relevant